Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04276441 · ClinicalTrials.gov registry record
A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World
A clinical trial, sponsored by Janssen Scientific Affairs.
- Completed
- Registry status
- 34,244
- Enrollment target
NCT04276441 is a clinical trial that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 34,244 participants.
The verdict
NCT04276441 has completed, sponsored by Janssen Scientific Affairs.
- COMPLETED
- Registry status
- 34,244 participants
- Enrollment target
Study Summary
The primary objectives of this study are to identify and diagnose Atrial Fibrillation (AF), evaluate improvement in cardiovascular (CV) outcomes, improve direct oral anti-coagulant (DOAC) adherence and persistence, and better characterize participants and identify predictors of disease.
Interventions
- DEVICE Heart healthy Engagement Program with the Apple Watch Series 5 or later
- DEVICE Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34,244 participants |
| Start Date | 2020-02-25 |
| Est. Completion | 2025-01-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04276441
The ClinicalTrials.gov registry entry for NCT04276441 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 34,244 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Scientific Affairs, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Heart healthy Engagement Program with the Apple Watch Series 5 or later is the first listed.
NCT04276441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04276441 about?
NCT04276441 is a clinical study titled "A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World". The primary objectives of this study are to identify and diagnose Atrial Fibrillation (AF), evaluate improvement in cardiovascular (CV) outcomes, improve direct oral anti-coagulant (DOAC) adherence and persistence, and better characterize participants and identify predictors of disease.
What is the current status of trial NCT04276441?
This trial is currently completed. The enrollment target is 34,244 participants. The study started on 2020-02-25. Estimated completion is 2025-01-23.
What interventions are being tested in trial NCT04276441?
The interventions under investigation include: Heart healthy Engagement Program with the Apple Watch Series 5 or later (DEVICE), Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later (DEVICE).
Who is sponsoring clinical trial NCT04276441?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.